Skip to main content
SpringerLink
Log in

Authors’ Reply to K. Langdon and Colleagues’ Comment on: “Botulinum Toxin in the Management of Children with Cerebral Palsy”

  • Letter to the Editor
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

The Original Article was published on 04 October 2019

The Original Article was published on 01 July 2019

A Review Article was published on 01 July 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Langdon K, Copeland L, Scheinberg A, Waugh MC, Burnett H, Wimalasundera N, et al. Comment on: “Botulinum toxin in the management of children with cerebral palsy”. Pediatr Drugs. 2019. https://doi.org/10.1007/s40272-019-00358-2.

    Article  Google Scholar 

  2. Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum toxin in the management of children with cerebral palsy. Pediatr Drugs. 2019;21(4):261–81.

    Article  Google Scholar 

  3. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67–79.

    Article  CAS  Google Scholar 

  4. Multani I, Manji J, Tang MJ, Herzog W, Howard JJ, Graham HK. Sarcopenia, cerebral palsy, and botulinum toxin type A. JBJS Rev. 2019;7(8):e4.

    Article  Google Scholar 

  5. Hastings-Ison T, Sangeux M, Thomason P, Rawicki B, Fahey M, Graham HK. Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study. J Child Orthop. 2018;12(4):390–7.

    Article  CAS  Google Scholar 

  6. Paget SP, Swinney CM, Burton KLO, Bau K, O'Flaherty SJ. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy. Dev Med Child Neurol. 2018;60(11):1172–7.

    Article  Google Scholar 

  7. Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G, et al. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017;59(3):329–34.

    Article  Google Scholar 

  8. Rodda JM, Graham HK, Carson L, Galea MP, Wolfe R. Sagittal gait patterns in spastic diplegia. J Bone Joint Surg Br. 2004;86(2):251–8.

    Article  CAS  Google Scholar 

  9. Valentine J, Davidson SA, Bear N, Blair E, Ward R, Thornton A, et al. Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat? Disabil Rehabil. 2019.  https://doi.org/10.1080/09638288.2019.1644381.

    Article  PubMed  Google Scholar 

  10. Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885–910.

    Article  Google Scholar 

  11. Hastings-Ison T, Graham K. Botulinum neurotoxin A, blinding, and bias. Dev Med Child Neurol. 2019. https://doi.org/10.1111/dmcn.14297.

    Article  PubMed  Google Scholar 

  12. Barber L, Hastings-Ison T, Baker R, Kerr Graham H, Barrett R, Lichtwark G. The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study. J Child Orthop. 2013;7(5):425–33.

    Article  Google Scholar 

  13. Schless SH, Cenni F, Bar-On L, Hanssen B, Kalkman B, O’Brien T, et al. Medial gastrocnemius volume and echo-intensity after botulinum neurotoxin A interventions in children with spastic cerebral palsy. Dev Med Child Neurol. 2019;61(7):783–90.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orthopaedic Department, Royal Children’s Hospital, Parkville, VIC, Australia

    Iqbal Multani & Jamil Manji

  2. Hugh Williamson Gait Laboratory, Royal Children’s Hospital, Parkville, VIC, Australia

    Tandy Hastings-Ison

  3. Royal Children’s Hospital, Parkville, VIC, Australia

    Abhay Khot

  4. University of Melbourne, The Royal Children’s Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia

    Kerr Graham

Authors
  1. Iqbal Multani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jamil Manji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tandy Hastings-Ison
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abhay Khot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kerr Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerr Graham.

Ethics declarations

Funding

Kerr Graham received non-financial support from the National Health and Medical Research Council of Australia (NHMRC) Centre of Research Excellence in Cerebral Palsy (CRE-CP). None of the authors received financial support for the publication of this letter.

Conflict of interest

Iqbal Multani, Jamil Manji,Tandy Hastings-Ison, Abhay Khot, and Kerr Graham have no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Multani, I., Manji, J., Hastings-Ison, T. et al. Authors’ Reply to K. Langdon and Colleagues’ Comment on: “Botulinum Toxin in the Management of Children with Cerebral Palsy”. Pediatr Drugs 21, 497–499 (2019). https://doi.org/10.1007/s40272-019-00359-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-019-00359-1

Search

Navigation